Fig. 2.
Comparison of soluble human leucocyte antigen (sHLA) class I between without (w/o) acute graft-versus-host disease (aGVHD) (n = 6) and aGVHD patients (n = 4) in the first month post allograft (day 30). sHLA class I level is significantly higher in the aGVHD group compared with the w/o aGVHD one in the first month post allograft [Mann–Whitney U-test: P < 0·01 (**)].